Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

President Donald Trump just sent letters to heads of 17 major pharmaceutical companies pushing them to drop drug prices in ...

Regeneron develops, manufactures, and markets medicines for serious diseases with a primary focus on immunology, ophthalmology, oncology, and rare conditions. Its scientific model centers on a robust ...

Following the sale of the direct-to-consumer genetic testing company 23andMe, the Utah Attorney General’s Office is issuing a ...

Two presentations discussed the significant care disruptions when there are copay assistance shortages, with patients ...

LONG BEACH, Calif. -- Concomitant treatment with drugs for geographic atrophy (GA) and neovascular macular degeneration (nAMD ...

An extension of a pivotal phase 3 trial shows that the functional and anatomic benefits of Eylea HD (aflibercept 8 milligram dose) have staying power in people with neovascular (wet) age-related ...

LONG BEACH, Calif. -- Outcomes in neovascular age-related macular degeneration (nAMD) failed to improve with the addition of ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2025 and reviewed recent ...

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.

In addition to DZ BANK AG, Sanofi also received a Buy from TR | OpenAI – 4o’s Veda Pharmyne in a report issued yesterday. However, on July 23, Deutsche Bank maintained a Hold rating on Sanofi (Other ...